|  |  |
| --- | --- |
| DEPARTMENT OF HEALTH SERVICESDivision of Care and Treatment ServicesF-24277 (05/2024) | STATE OF WISCONSIN42 CFR483.420(a)(2)DHS 134.31(3)(o)DHS 94.03 & 94.09§§ 51.61(1)(g) & (h) |

|  |
| --- |
| INFORMED CONSENT FOR MEDICATIONDosage and / or Side Effect information last revised on 05/27/2021Completion of this form is voluntary. If informed consent is not given, the medication cannot be administered without a court order unless in an emergency.This consent is maintained in the client’s record and is accessible to authorized users. |
| Name – Patient / Client (Last, First MI)     ,             | ID Number      | Living Unit      | Date of Birth      |
| Name – Individual Preparing This Form      | Name – Staff Contact      | Name / Telephone Number – Institution      |
| MEDICATION CATEGORY | **MEDICATION** | RECOMMENDED**DAILY TOTAL DOSAGE RANGE** | ANTICIPATED DOSAGE RANGE |
| Central Nervous System Stimulant | Adderall; Adderall XR(dextroamphetamine and amphetamine) | Immediate release: 2.5 mg – 40 mgExtended release: 5 mg - 40 mg |       |
| The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent.Recommended daily total dosage range of manufacturer, as stated in *Physician’s Desk Reference* (PDR) or another standard reference.This medication will be administered [ ]  Orally [ ]  Injection [ ]  Other – Specify:       |
| Reason for Use of Psychotropic Medication and Benefits Expected (note if this is ‘Off-Label’ Use)Include DSM-5 diagnosis or the diagnostic impression (“working hypothesis.”) |
|       |
| **2. Alternative mode(s) of treatment other than OR in addition to medications include**Note: Some of these would be applicable only in an inpatient environment. |
| [ ]  Environment and/or staff changes | [ ]  Rehabilitation treatments/therapy (OT, PT, AT) |
| [ ]  Positive redirection and staff interaction | [ ]  Treatment programs and approaches (habilitation) |
| [ ]  Individual and/or group therapy | [ ]  Use of behavior intervention techniques |
| **Other Alternatives**:       |
| 3. Probable consequences of NOT receiving the proposed medication are |
| Impairment of [ ]  Work Activities  | [ ]  Family Relationships | [ ]  Social Functioning |
|  |  |  |
| Possible increase in symptoms leading to potential |  |
| [ ]  Use of seclusion or restraint | [ ]  Limits on recreation and leisure activities |
| [ ]  Limits on access to possessions | [ ]  Intervention of law enforcement authorities |
| [ ]  Limits on personal freedoms | [ ]  Risk of harm to self or others |
| [ ]  Limit participation in treatment and activities |  |
| **Other Consequences**:       |
|  Note: These consequences may vary depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered. |

See Page 2

| F-24277  | Medication: Adderall;Adderall XR - (dextroamphetamine and amphetamine) |
| --- | --- |
| Possible side effects, warnings, and cautions associated with this medication are listed below. This is not an all-inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text, such as the PDR. As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects in order to enhance care and treatment. |
| Continued – Possible side effects, warnings, and cautions associated with this medication.Most Common Side Effects: Anxiety; crying; depersonalization; dry mouth; dysphoria; euphoria; fast, pounding, or irregular heartbeat or pulse; hyperventilation; irritability; mental depression; nervousness; paranoia; quick to react or overreact emotionally; rapidly changing moods; restlessness; shaking; shortness of breath; trouble sleeping; false sense of well-being. After these stimulant effects have worn off, drowsiness, trembling, unusual tiredness or weakness may occur.  |
| **Less Common Side Effects:** Increased risk of infection; lower back or side pain with painful or difficult urination; tightness in chest; wheezing; accidental injury; bloody or cloudy urine; blurred vision; changes in sexual desire or decreased sexual ability; constipation; cramps; diarrhea; difficulty forming words or sentences; dizziness or lightheadedness; headache; heavy bleeding with menstrual period; inability to have or keep an erection; increased sensitivity of skin to sunlight; increased sweating; itching, redness or other discoloration of skin; loss of appetite; nausea or vomiting; sleepiness or unusual drowsiness; tooth infection; twitching; weight loss. |
| **Rare Side Effects:** Check with your doctor immediately if any of the following rare side effects occur: Chest pain; high fever; skin rash or hives; uncontrolled movements of head, neck, arms, and legs; difficulty breathing; swelling of the face, tongue, or lips. |
| **Caution*** **Withdrawal**

Do not suddenly stop taking this medication. If this medication is suddenly stopped after taking for a longer period of time (months), drowsiness, trembling, unusual tiredness or weakness, or mental depression may occur. Also, with long-term use or high doses, you may experience difficulty breathing; dizziness or feeling faint; increased blood pressure; mood or mental changes; pounding heartbeat. When considering stopping this medication, please speak with your doctor. * **Driving and Operating Heavy Machinery**

This medication may cause you to feel dizzy or drowsy. It is recommended to avoid driving, operating heavy machinery, or performing any other task that may be dangerous if not fully alert until you know how this medication affects you. * **Serotonin Syndrome**

Potentially life-threatening serotonin syndrome (SS) may occur when dextroamphetamine/amphetamine is used in combination with other serotonergic agents (eg, SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, St. John's wort, tryptophan), agents that impair metabolism of serotonin (eg, MAOIs) or CYP2D6 inhibitors that impair metabolism of dextroamphetamine/amphetamine. Use of these drugs with MAOIs is contraindicated. If use of dextroamphetamine/amphetamine with serotonergic drugs or CYP2D6 inhibitors is needed, initiate dextroamphetamine/amphetamine at a low dose and monitor patient closely for signs and symptoms of SS. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.* **Altered Appetite in Children**

Appetite suppression may occur; particularly in children. Use of stimulants has been associated with weight loss and slowing growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected.* **Seizures**

If you experience seizures while taking this medication, please call your doctor promptly. * **Vision Changes**

If you notice changes in your vision, including blurry vision, please call your doctor right away. |
| **Warning: [Black Box Warning]: Amphetamines have a high potential for abuse.** Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others, and the drugs should be prescribed or dispensed sparingly. Administration of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided.**Warning: [Black Box Warning]: Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events.**CNS stimulants, such as Adderall, may increase heart rate and blood pressure; in pediatric patients, the observed mean increase in heart rate was 3 to 6 bpm and blood pressure was 2 to 4 mm Hg. Use with caution in patients with hypertension, heart failure, recent MI, ventricular arrhythmia, and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Some products are contraindicated in patients with moderate to severe hypertension or hyperthyroidism. |
| See standard reference text for an all-inclusive list of side effects. |
| By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather, it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal.
2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements.
3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client’s social worker, case manager, or psychologist.
4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b).
5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client’s social worker, case manager, or agency/facility client rights specialist may be contacted for assistance.
6. My consent permits the dose to be changed within the **anticipated dosage range** without signing another consent.
7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s), and the probable consequences that may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate, and complete.
8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose.
 |

|  |  |
| --- | --- |
| **SIGNATURES** | **DATE SIGNED** |
| Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC) | Relationship to Client [ ]  Self[ ]  Parent [ ]  Guardian (POA-HC) |  |
| Staff Present at Oral Discussion | Title |  |
| Client / Parent of Minor / Guardian (POA-HC) Comments |
| **As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.** |
| **Verbal Consent** |
| Obtained by – PRINT – Staff Name | Date Obtained | Written Consent Received[ ]  Yes [ ]  No |
| Obtained from – PRINT – Parent / Guardian (POA-HC) Name | Date Expires | Date Received |